Skip to main content
SpringerLink
Log in

Increase of serum fractalkine and fractalkine gene expression levels in sickle cell disease patients

  • Original Article
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

In the present study, we examined the role of fractalkine (Fkn), a member of the chemokine family, in the pathogenesis of sickle cell disease (SCD). Eighty-seven children with sickle cell disease and 55 healthy children were enrolled in the study. Complete blood counts, serum levels of C-reactive protein, tumor necrosis factor-α, interferon-γ and fractalkine, and gene expression levels of Fkn were investigated. Serum Fkn levels and Fkn gene expression values were significantly higher in the SCD group compared to control group (P < 0.05). The findings of elevated serum Fkn and Fkn gene expression in both vaso-occlusive crisis and stable forms of SCD suggest that this chemokine may be involved in the pathogenesis of inflammation observed in SCD. This study is the first to our knowledge to describe the relationship of Fkn and inflammation in SCD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Rother RP, Bell L, Hillmen P, Gladwin MT. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. JAMA. 2005;293:1653–62.

    Article  CAS  PubMed  Google Scholar 

  2. Makis AC, Hatzimichael EC, Bourantas KL. The role of cytokines in sickle cell disease. Ann Hematol. 2000;79:407–13.

    Article  CAS  PubMed  Google Scholar 

  3. Ballas SK. The sickle cell painful crisis in adults: phases and objective signs. Hemoglobin. 1995;19:323–33.

    Article  CAS  PubMed  Google Scholar 

  4. Platt OS. Sickle cell anemia as an inflammatory disease. J Clin Invest. 2000;106:337–8.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  5. Pathare A, Al Kindi S, Alnaqdy AA, Daar S, Knox-Macaulay H, Dennison D. Cytokine profile of sickle cell disease in Oman. Am J Hematol. 2004;77:323–8.

    Article  CAS  PubMed  Google Scholar 

  6. Pathare A, Kindi SA, Daar S, Dennison D. Cytokines in sickle cell disease. Hematology. 2003;8:329–37.

    Article  CAS  PubMed  Google Scholar 

  7. Bourantas KL, Dalekos GN, Makis A, Chaidos A, Tsiara S, Mavridis A. Acute phase proteins and interleukins in steady state sickle cell disease. Eur J Haematol. 1998;61:49–54.

    Article  CAS  PubMed  Google Scholar 

  8. Belcher JD, Bryant CJ, Nguyen J, Bowlin PR, Kielbik MC, Bischof JC, Hebbel RP, Vercellotti GM. Transgenic sickle mice have vascular inflammation. Blood. 2003;101:3953–9.

    Article  CAS  PubMed  Google Scholar 

  9. Vercellotti GM, Belcher JD. Not simply misshapen red cells: multimolecular and cellular events in sickle vaso-occlusion. J Clin Invest. 2014;124:1462–5.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  10. Wojdasiewicz P, Poniatowski LA, Kotela A, Deszczynski J, Kotela I, Szukiewicz D. The chemokine CX3CL1 (fractalkine) and its receptor CX3CR1: occurrence and potential role in osteoarthritis. Arch Immunol Ther Exp (Warsz). 2014;62:395–403.

    Article  CAS  Google Scholar 

  11. White GE, Greaves DR. Fractalkine: one chemokine, many functions. Blood. 2009;113:767–8.

    Article  CAS  PubMed  Google Scholar 

  12. Landsman L, Bar-On L, Zernecke A, Kim KW, Krauthgamer R, Shagdarsuren E, Lira SA, Weissman IL, Weber C, Jung S. CX3CR1 is required for monocyte homeostasis and atherogenesis by promoting cell survival. Blood. 2009;113:963–72.

    Article  CAS  PubMed  Google Scholar 

  13. Avni T, Paret G, Thaler A, Mishali D, Yishay S, Tal G, Dalal I. Delta chemokine (fractalkine)–a novel mediator of pulmonary arterial hypertension in children undergoing cardiac surgery. Cytokine. 2010;52:143–5.

    Article  CAS  PubMed  Google Scholar 

  14. Jones BA, Riegsecker S, Rahman A, Beamer M, Aboualaiwi W, Khuder S, Ahmed S. Role of ADAM-17, p38 MAPK, cathepsins, and the proteasome pathway in the synthesis and shedding of fractalkine/CX3CL1 in rheumatoid arthritis. Arthritis Rheum. 2013;65:2814–25.

    Article  CAS  PubMed  Google Scholar 

  15. Fujimoto K, Imaizumi T, Yoshida H, Takanashi S, Okumura K, Satoh K. Interferon-gamma stimulates fractalkine expression in human bronchial epithelial cells and regulates mononuclear cell adherence. Am J Respir Cell Mol Biol. 2001;25:233–8.

    Article  CAS  PubMed  Google Scholar 

  16. Umehara H, Bloom ET, Okazaki T, Nagano Y, Yoshie O, Imai T. Fractalkine in vascular biology: from basic research to clinical disease. Arterioscler Thromb Vasc Biol. 2004;24:34–40.

    Article  CAS  PubMed  Google Scholar 

  17. Yoneda O, Imai T, Nishimura M, Miyaji M, Mimori T, Okazaki T, Domae N, Fujimoto H, Minami Y, Kono T, Bloom ET, Umehara H. Membrane-bound form of fractalkine induces IFN-γ production by NK cells. Eur J Immunol. 2003;33:53–8.

    Article  CAS  PubMed  Google Scholar 

  18. Jang JE, Hod EA, Spitalnik SL, Frenette PS. CXCL1 and its receptor, CXCR2, mediate murine sickle cell vaso-occlusion during hemolytic transfusion reactions. J Clin Invest. 2011;121:1397–401.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  19. Qari MH, Dier U, Mousa SA. Biomarkers of inflammation, growth factor, and coagulation activation in patients with sickle cell disease. Clin Appl Thromb Hemost. 2012;18:195–200.

    Article  CAS  PubMed  Google Scholar 

  20. Driss A, Wilson NO, Mason K, Hyacinth HI, Hibbert JM, Serjeant GR, Stiles JK. Elevated IL-1alpha and CXCL10 serum levels occur in patients with homozygous sickle cell disease and a history of acute splenic sequestration. Dis Markers. 2012;32:295–300.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  21. Ostadebrahimi H, Jamali Z, Nazari M, Bahri M, Farahmandnia Z, Khandany BK, Taheri M, Khorramdelazad H, Hakimizadeh E, Zaker F, Rezaeian M, Hassanshahi G. CXC chemokines CXCL1, CXCL9, CXCL10 and CXCL12 are variably expressed in patients with sickle cell disease and carriers: are they predictive tools for disease complications? Clin Lab. 2014;60:99–104.

    CAS  PubMed  Google Scholar 

  22. Veiga PC, Schroth RJ, Guedes R, Freire SM, Nogueira-Filho G. Serum cytokine profile among Brazilian children of African descent with periodontal inflammation and sickle cell anaemia. Arch Oral Biol. 2013;58:505–10.

    Article  CAS  PubMed  Google Scholar 

  23. Walter PB, Fung EB, Killilea DW, Jiang Q, Hudes M, Madden J, Porter J, Evans P, Vichinsky E, Harmatz P. Oxidative stress and inflammation in iron-overloaded patients with beta-thalassaemia or sickle cell disease. Br J Haematol. 2006;135:254–63.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  24. Raghupathy R, Haider MZ, Azizieh F, D’Souza TM, Abdelsalam R, Adekile AD. Tumor necrosis factor-alpha is undetectable in the plasma of SS patients with elevated Hb F. Am J Hematol. 2000;64:91–4.

    Article  CAS  PubMed  Google Scholar 

  25. Yajima N, Kasama T, Isozaki T, Odai T, Matsunawa M, Negishi M, Ide H, Kameoka Y, Hirohata S, Adachi M. Elevated levels of soluble fractalkine in active systemic lupus erythematosus: potential involvement in neuropsychiatric manifestations. Arthritis Rheum. 2005;52:1670–5.

    Article  CAS  PubMed  Google Scholar 

  26. Perros F, Dorfmuller P, Souza R, Durand-Gasselin I, Godot V, Capel F, Adnot S, Eddahibi S, Mazmanian M, Fadel E, Herve P, Simonneau G, Emilie D, Humbert M. Fractalkine-induced smooth muscle cell proliferation in pulmonary hypertension. Eur Respir J. 2007;29:937–43.

    Article  CAS  PubMed  Google Scholar 

  27. Blaschke S, Koziolek M, Schwarz A, Benohr P, Middel P, Schwarz G, Hummel KM, Muller GA. Proinflammatory role of fractalkine (CX3CL1) in rheumatoid arthritis. J Rheumatol. 2003;30:1918–27.

    CAS  PubMed  Google Scholar 

  28. Dimberg J, Dienus O, Lofgren S, Hugander A, Wagsater D. Polymorphisms of Fractalkine receptor CX3CR1 and plasma levels of its ligand CX3CL1 in colorectal cancer patients. Int J Colorectal Dis. 2007;22:1195–200.

    Article  PubMed  Google Scholar 

  29. Rimaniol AC, Till SJ, Garcia G, Capel F, Godot V, Balabanian K, Durand-Gasselin I, Varga EM, Simonneau G, Emilie D, Durham SR, Humbert M. The CX3C chemokine fractalkine in allergic asthma and rhinitis. J Allergy Clin Immunol. 2003;112:1139–46.

    Article  CAS  PubMed  Google Scholar 

  30. Alexander RW. Cytokine receptor CX3CR-1 and fractalkine: new factors in the atherosclerosis drama? Circ Res. 2001;89:376–7.

    CAS  PubMed  Google Scholar 

  31. Sallusto F, Mackay CR, Lanzavecchia A. The role of chemokine receptors in primary, effector, and memory immune responses. Annu Rev Immunol. 2000;18:593–620.

    Article  CAS  PubMed  Google Scholar 

  32. Matsunawa M, Isozaki T, Odai T, Yajima N, Takeuchi HT, Negishi M, Ide H, Adachi M, Kasama T. Increased serum levels of soluble fractalkine (CX3CL1) correlate with disease activity in rheumatoid vasculitis. Arthritis Rheum. 2006;54:3408–16.

    Article  CAS  PubMed  Google Scholar 

  33. Niessner A, Marculescu R, Kvakan H, Haschemi A, Endler G, Weyand CM, Maurer G, Mannhalter C, Wojta J, Wagner O, Huber K. Fractalkine receptor polymorphisms V2491 and T280 M as genetic risk factors for restenosis. Thromb Haemost. 2005;94:1251–6.

    CAS  PubMed  Google Scholar 

  34. Flierl U, Schafer A. Fractalkine–a local inflammatory marker aggravating platelet activation at the vulnerable plaque. Thromb Haemost. 2012;108:457–63.

    Article  CAS  PubMed  Google Scholar 

  35. Truman LA, Ford CA, Pasikowska M, Pound JD, Wilkinson SJ, Dumitriu IE, Melville L, Melrose LA, Ogden CA, Nibbs R, Graham G, Combadiere C, Gregory CD. CX3CL1/fractalkine is released from apoptotic lymphocytes to stimulate macrophage chemotaxis. Blood. 2008;112:5026–36.

    Article  CAS  PubMed  Google Scholar 

  36. Corcione A, Ferretti E, Pistoia V. CX3CL1/fractalkine is a novel regulator of normal and malignant human B cell function. J Leukoc Biol. 2012;92:51–8.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatric Hematology, Faculty of Medicine, Mersin University, Mersin, Turkey

    Selma Unal & Ozlem Ozdemir

  2. Department of Biology, Faculty of Science and Literature, Mersin University, Mersin, Turkey

    Ahmet Ata Ozcimen

  3. Department of Biochemistry, Faculty of Medicine, Hacettepe University, Ankara, Turkey

    Yesim Oztas

Authors
  1. Selma Unal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ozlem Ozdemir
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ahmet Ata Ozcimen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yesim Oztas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yesim Oztas.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Unal, S., Ozdemir, O., Ozcimen, A.A. et al. Increase of serum fractalkine and fractalkine gene expression levels in sickle cell disease patients. Int J Hematol 101, 114–118 (2015). https://doi.org/10.1007/s12185-014-1718-4

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-014-1718-4

Keywords

Search

Navigation